Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guldbrandsen Kasper Foged, Bloch Martin, Skougaard Kristin, Ahlborn Lise Barlebo, Jakobsen Erik, Højsgaard Anette, Petersen Rene Horsleben, Møller Lars Borgbjerg, Dahl Morten, Sorensen Boe Sandahl, Frank Malene Støchkel, Ehlers Jeanette Haar, Krakauer Martin, Gørtz Peter Michael, Albrecht-Beste Elisabeth, Grüner Julie Marie, Saghir Zaigham, Fledelius Joan, Nielsen Anne Lerberg, Holdgaard Paw Christian, Nielsen Søren Steen, Pøhl Mette, Borissova Svetlana, Land Lotte Holm, Kristiansen Charlotte, McCulloch Tine, Mortensen Lise Saksø, Nellemann Hanne Marie, Christophersen Malene Søby, Hilberg Ole, Rasmussen Thor Lind, Schwaner Signe Høyer Simonsen, Laursen Christian B, Bodtger Uffe, Sopina Liza, Lonsdale Markus Nowak, Meyer Christian Niels, Gerke Oke, Mortensen Jann, Rasmussen Torben Riis, Fischer Barbara Malene, SUPE_R Study Group
Аннотация
METHODS: In this multicenter, randomized controlled trial (SUPE_R, ClinicalTrials.gov NCT03740126), patients with stage IA-to-IIIC NSCLC were randomized one-to-one to standard surveillance (ceCT) or surveillance with [18F]FDG PET/CT after completion of curative treatment. The primary outcome was the proportion of recurrences treated with curative intent. Secondary outcomes included time to recurrence (TTR) and overall survival (OS).
RESULTS: Between February 2019 and February 2022, 750 patients were randomized to PET/CT (n = 373) or CT (n = 377). Recurrences occurred in 164 patients (22%). The proportion of recurrences treated with curative intent was identical in the PET group (42/87) and CT group (37/77), both 48% (p = 0.98). More recurrences were detected through scheduled follow-up in the PET group (90%) than in the CT group (77%; p = 0.02). There were no significant differences in TTR (hazard ratio 1.12, 95% confidence interval 0.82-1.52, p = 0.48) or OS (hazard ratio 0.97, 95% confidence interval 0.66-1.43, p = 0.89) between groups.
CONCLUSIONS: Surveillance with [18F]FDG PET/CT did not improve rates of curatively treated recurrences, TTR, or OS compared with ceCT in patients with NSCLC after curative treatment. These findings do not support the routine use of [18F]FDG PET/CT for post-treatment surveillance in this patient population.